Scotiabank Keeps Their Buy Rating on Biodesix (BDSX)
TipRanks (Wed, 5-Mar 8:19 AM ET)
Biodesix, Inc. Reports Strong Growth Amid Financial Challenges
TipRanks (Tue, 4-Mar 7:21 PM ET)
TipRanks (Tue, 4-Mar 5:15 PM ET)
Biodesix: Strong Financial Performance and Positive Growth Outlook Justify Buy Rating
TipRanks (Tue, 4-Mar 8:55 AM ET)
Biodesix: Strong Growth and Promising Future with Buy Rating from Kyle Mikson CFA
TipRanks (Tue, 4-Mar 6:57 AM ET)
Benzinga (Tue, 4-Mar 6:07 AM ET)
Biodesix: Promising Financial Outlook and Strategic Execution Justify Buy Rating
TipRanks (Tue, 4-Mar 5:45 AM ET)
Biodesix Reports Strong 2024 Financial Performance
TipRanks (Mon, 3-Mar 11:01 PM ET)
Biodesix GAAP EPS of -$0.06 beats by $0.01, revenue of $20.42M beats by $0.5M
Seeking Alpha News (Mon, 3-Mar 4:06 PM ET)
Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results
Globe Newswire (Mon, 3-Mar 4:01 PM ET)
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
Biodesix trades on the NASDAQ stock market under the symbol BDSX.
As of March 5, 2025, BDSX stock price climbed to $0.87 with 825,972 million shares trading.
BDSX has a beta of 1.10, meaning it tends to be more sensitive to market movements. BDSX has a correlation of 0.06 to the broad based SPY ETF.
BDSX has a market cap of $126.30 million. This is considered a Micro Cap stock.
Last quarter Biodesix reported $20 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $629,000 and exceeded earnings estimates by $.01.
In the last 3 years, BDSX traded as high as $3.00 and as low as $.64.
The top ETF exchange traded funds that BDSX belongs to (by Net Assets): VTI, VXF, IWC.
BDSX has underperformed the market in the last year with a price return of -43.9% while the SPY ETF gained +15.2%. BDSX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.6% and -10.3%, respectively, while the SPY returned -3.7% and -4.6%, respectively.
BDSX support price is $.68 and resistance is $.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BDSX shares will trade within this expected range on the day.